• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MiR-106a在人胶质瘤U87/DDP和U251/G细胞系多药耐药逆转中的作用及分子机制

The Effects and Molecular Mechanisms of MiR-106a in Multidrug Resistance Reversal in Human Glioma U87/DDP and U251/G Cell Lines.

作者信息

Wang Qin, Wang Zhenlian, Chu LinYang, Li Xu, Kan Pengcheng, Xin Xin, Zhu Yu, Yang Ping

机构信息

Department of Clinical Laboratory, Tianjin Huanhu Hospital, Tianjin Key Laboratory of Cerebral Vessels and Neural Degeneration, Tianjin 300060, China.

Department of Nursing, School of Pharmaceutical Engineering and Life Science, Changzhou University, Changzhou 213164, China; School of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical College, Wenzhou 325003, China.

出版信息

PLoS One. 2015 May 7;10(5):e0125473. doi: 10.1371/journal.pone.0125473. eCollection 2015.

DOI:10.1371/journal.pone.0125473
PMID:25950430
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4423781/
Abstract

Chemotherapy resistance is one of the major obstacles to effective glioma therapy. Currently, the mechanism underlying chemotherapy resistance is unclear. A recent study showed that miR-106a is an important molecule involved in chemotherapy resistance. To explore the effects and mechanisms of miR-106a on multidrug resistance reversal in human glioma cells, we silenced miR-106a expression in the cisplatin-resistant U87 (U87/DDP) and the gefitinib-resistant U251 (U251/G) glioma cell lines and measured the resulting drug sensitivity, cell apoptosis rate and rhodamine 123 content. In addition, we detected decreased expression of P-glycoprotein, MDR1, MRP1, GST-π, CDX2, ERCC1, RhoE, Bcl-2, Survivin and Topo-II, as well as reduced production of IL-6, IL-8 and TGF-β in these cell lines. Furthermore, we found decreased expression of p-AKT and transcriptional activation of NF-κB, Twist, AP-1 and Snail in these cell lines. These results suggest that miR-106a is a promising therapeutic target for the treatment of human multidrug resistant glioma.

摘要

化疗耐药是有效治疗胶质瘤的主要障碍之一。目前，化疗耐药的潜在机制尚不清楚。最近的一项研究表明，miR-106a是参与化疗耐药的重要分子。为了探讨miR-106a对人胶质瘤细胞多药耐药逆转的影响及机制，我们在顺铂耐药的U87（U87/DDP）和吉非替尼耐药的U251（U251/G）胶质瘤细胞系中沉默miR-106a的表达，并检测由此产生的药物敏感性、细胞凋亡率和罗丹明123含量。此外，我们检测到这些细胞系中P-糖蛋白、MDR1、MRP1、GST-π、CDX2、ERCC1、RhoE、Bcl-2、Survivin和Topo-II的表达降低，以及IL-6、IL-8和TGF-β的产生减少。此外，我们发现这些细胞系中p-AKT的表达降低，NF-κB、Twist、AP-1和Snail的转录激活减少。这些结果表明，miR-106a是治疗人多药耐药胶质瘤的一个有前景的治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d3d/4423781/f9326ae2f278/pone.0125473.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d3d/4423781/73703f4ebfad/pone.0125473.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d3d/4423781/f569bab9e9f6/pone.0125473.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d3d/4423781/e783371741a2/pone.0125473.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d3d/4423781/beea609b6076/pone.0125473.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d3d/4423781/ede05eaae965/pone.0125473.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d3d/4423781/f9326ae2f278/pone.0125473.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d3d/4423781/73703f4ebfad/pone.0125473.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d3d/4423781/f569bab9e9f6/pone.0125473.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d3d/4423781/e783371741a2/pone.0125473.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d3d/4423781/beea609b6076/pone.0125473.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d3d/4423781/ede05eaae965/pone.0125473.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d3d/4423781/f9326ae2f278/pone.0125473.g007.jpg

相似文献

1
The Effects and Molecular Mechanisms of MiR-106a in Multidrug Resistance Reversal in Human Glioma U87/DDP and U251/G Cell Lines.MiR-106a在人胶质瘤U87/DDP和U251/G细胞系多药耐药逆转中的作用及分子机制
PLoS One. 2015 May 7;10(5):e0125473. doi: 10.1371/journal.pone.0125473. eCollection 2015.
2
[The reversing and molecular mechanisms of miR-503 on the drug-resistance to cisplatin in A549/DDP cells].[miR-503对A549/DDP细胞顺铂耐药的逆转作用及分子机制]
Zhongguo Fei Ai Za Zhi. 2014 Jan;17(1):1-7. doi: 10.3779/j.issn.1009-3419.2014.01.01.
3
MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1.微小RNA-106a通过靶向三磷酸腺苷结合盒转运体A1赋予非小细胞肺癌A549细胞顺铂耐药性。
Mol Med Rep. 2015 Jan;11(1):625-32. doi: 10.3892/mmr.2014.2688. Epub 2014 Oct 17.
4
Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells.敲低微小RNA-127可通过使阿霉素耐药的人胶质瘤细胞发生细胞周期阻滞和凋亡致敏来逆转阿霉素耐药。
Int J Clin Exp Pathol. 2015 Jun 1;8(6):6107-16. eCollection 2015.
5
Is mda-7/IL-24 a potential target and biomarker for enhancing drug sensitivity in human glioma U87 cell line?mda-7/IL-24 是否可作为增强人脑胶质瘤 U87 细胞系药物敏感性的潜在靶点和生物标志物？
Anat Rec (Hoboken). 2013 Aug;296(8):1154-60. doi: 10.1002/ar.22723. Epub 2013 Jun 24.
6
Migration-prone glioma cells show curcumin resistance associated with enhanced expression of miR-21 and invasion/anti-apoptosis-related proteins.易于迁移的胶质瘤细胞表现出姜黄素抗性，这与miR-21以及侵袭/抗凋亡相关蛋白的表达增强有关。
Oncotarget. 2015 Nov 10;6(35):37770-81. doi: 10.18632/oncotarget.6092.
7
Cytokine-induced killer cells induce apoptosis and inhibit the Akt/nuclear factor-κB signaling pathway in cisplatin-resistant human glioma U87MG cells.细胞因子诱导的杀伤细胞诱导顺铂耐药的人胶质瘤U87MG细胞凋亡并抑制Akt/核因子-κB信号通路。
Mol Med Rep. 2015 Nov;12(5):7027-32. doi: 10.3892/mmr.2015.4236. Epub 2015 Aug 21.
8
MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.微小RNA-133b靶向谷胱甘肽S-转移酶π的表达以增加卵巢癌细胞对化疗药物的敏感性。
Drug Des Devel Ther. 2015 Sep 16;9:5225-35. doi: 10.2147/DDDT.S87526. eCollection 2015.
9
Regulation of mTOR by miR-107 to facilitate glioma cell apoptosis and to enhance cisplatin sensitivity.miR-107 通过调控 mTOR 促进胶质瘤细胞凋亡并增强顺铂敏感性
Eur Rev Med Pharmacol Sci. 2018 Oct;22(20):6864-6872. doi: 10.26355/eurrev_201810_16155.
10
shRNA-mediated silencing of sorcin increases drug chemosensitivity in myeloma KM3/DDP and U266/ADM cell lines.短发夹RNA介导的索辛沉默增加了骨髓瘤KM3/DDP和U266/ADM细胞系的药物化学敏感性。
Int J Clin Exp Pathol. 2015 Mar 1;8(3):2300-10. eCollection 2015.

引用本文的文献

1
Overview of miR-106a Regulatory Roles: from Cancer to Aging.miR-106a调控作用概述：从癌症到衰老
Bioengineering (Basel). 2023 Jul 27;10(8):892. doi: 10.3390/bioengineering10080892.
2
Zinc Finger E-Box Binding Homeobox Family: Non-Coding RNA and Epigenetic Regulation in Gliomas.锌指E盒结合同源框家族：胶质瘤中的非编码RNA与表观遗传调控
Biomedicines. 2023 May 5;11(5):1364. doi: 10.3390/biomedicines11051364.
3
Exosome-based strategies for diagnosis and therapy of glioma cancer.基于外泌体的神经胶质瘤癌症诊断与治疗策略。

本文引用的文献

1
Anti-EGFR function of EFEMP1 in glioma cells and patient prognosis.EFEMP1在胶质瘤细胞中的抗表皮生长因子受体（EGFR）功能与患者预后
Oncoscience. 2014 Mar 25;1(3):205-15. doi: 10.18632/oncoscience.24. eCollection 2014.
2
Association of genetic polymorphisms of EGFR with glioma in a Chinese population.中国人群中表皮生长因子受体基因多态性与胶质瘤的关联
Genet Test Mol Biomarkers. 2015 Jan;19(1):59-62. doi: 10.1089/gtmb.2014.0228.
3
Glioma biology and molecular markers.胶质瘤生物学与分子标志物
Cancer Cell Int. 2022 Aug 21;22(1):262. doi: 10.1186/s12935-022-02642-7.
4
The Mechanisms of Current Platinum Anticancer Drug Resistance in the Glioma.脑胶质瘤中当前铂类抗癌药物耐药的机制。
Curr Pharm Des. 2022;28(23):1863-1869. doi: 10.2174/1381612828666220607105746.
5
NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review).ncRNAs：多角度参与调控胶质瘤化疗抵抗（综述）。
Int J Oncol. 2022 Jun;60(6). doi: 10.3892/ijo.2022.5366. Epub 2022 May 4.
6
Curcumin alters distinct molecular pathways in breast cancer subtypes revealed by integrated miRNA/mRNA expression analysis.姜黄素通过整合 miRNA/mRNA 表达分析改变乳腺癌亚型中的不同分子途径。
Cancer Rep (Hoboken). 2022 Oct;5(10):e1596. doi: 10.1002/cnr2.1596. Epub 2022 Jan 4.
7
miR-106a Targets Anoctamin 1 (ANO1) to Regulate Lipopolysaccharide (LPS)-Induced Inflammatory Response in Macrophages.微小RNA-106a靶向anoctamin 1（ANO1）以调节脂多糖（LPS）诱导的巨噬细胞炎症反应。
Med Sci Monit. 2020 Oct 10;26:e922479. doi: 10.12659/MSM.922479.
8
Antioxidant and Anticancer Activity of Novel Derivatives of 3-[(4-Methoxyphenyl)amino]propane-hydrazide.新型 3-[(4-甲氧基苯基)氨基]丙酰肼衍生物的抗氧化和抗癌活性。
Molecules. 2020 Jun 29;25(13):2980. doi: 10.3390/molecules25132980.
9
Noncoding RNAs: the shot callers in tumor immune escape.非编码 RNA：肿瘤免疫逃逸中的发号施令者。
Signal Transduct Target Ther. 2020 Jun 19;5(1):102. doi: 10.1038/s41392-020-0194-y.
10
MicroRNA-9 enhances chemotherapy sensitivity of glioma to TMZ by suppressing TOPO II via the NF-κB signaling pathway.微小RNA-9通过核因子κB信号通路抑制拓扑异构酶II，增强胶质瘤对替莫唑胺的化疗敏感性。
Oncol Lett. 2019 Jun;17(6):4819-4826. doi: 10.3892/ol.2019.10158. Epub 2019 Mar 18.
Cancer Treat Res. 2015;163:15-30. doi: 10.1007/978-3-319-12048-5_2.
4
Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting the NF-κB/Bcl‑2 pathway.骨桥蛋白的下调通过靶向NF-κB/Bcl-2信号通路增强胶质瘤U251细胞对替莫唑胺和顺铂的敏感性。
Mol Med Rep. 2015 Mar;11(3):1951-5. doi: 10.3892/mmr.2014.2951. Epub 2014 Nov 14.
5
Alkylglyceronephosphate synthase (AGPS) alters lipid signaling pathways and supports chemotherapy resistance of glioma and hepatic carcinoma cell lines.烷基甘油磷酸合酶（AGPS）改变脂质信号通路，并支持胶质瘤和肝癌细胞系的化疗耐药性。
Asian Pac J Cancer Prev. 2014;15(7):3219-26. doi: 10.7314/apjcp.2014.15.7.3219.
6
Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2.致癌 miRNA-20a 和 miRNA-106a 通过直接靶向 TIMP-2 增强人神经胶质瘤干细胞的侵袭性。
Oncogene. 2015 Mar 12;34(11):1407-19. doi: 10.1038/onc.2014.75. Epub 2014 Apr 7.
7
Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer.晚期非小细胞肺癌患者在吉非替尼或厄洛替尼治疗失败后的再次治疗。
J Thorac Dis. 2013 Aug;5(4):400-5. doi: 10.3978/j.issn.2072-1439.2013.07.28.
8
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy.白细胞介素-17 介导的旁分泌网络促进肿瘤对抗血管生成治疗的耐药性。
Nat Med. 2013 Sep;19(9):1114-23. doi: 10.1038/nm.3291. Epub 2013 Aug 4.
9
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.EGFR 酪氨酸激酶抑制剂吉非替尼/厄洛替尼和 ALK 抑制剂克唑替尼耐药的机制。
Lung Cancer. 2013 Sep;81(3):328-336. doi: 10.1016/j.lungcan.2013.05.020. Epub 2013 Jun 25.
10
Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer.miR-106a 和 miR-591 的失调赋予卵巢癌细胞紫杉醇耐药性。
Br J Cancer. 2013 Jul 23;109(2):452-61. doi: 10.1038/bjc.2013.305. Epub 2013 Jun 27.